FROM 01 Dec Myfortic will be
listed on the Pharmaceutical
Benefits Scheme for Australians
living with lupus nephritis.
The approval provides a
treatment option for up to 2,000
Australians with this potentially life
threatening kidney disorder (which
causes inflammation of the kidney
and can result in mild, moderate or
severe kidney damage).
“I think this is a great outcome for
patients with lupus nephritis,” said
Dr Richard Phoon, Senior Staff
Specialist in Nephrology at
Westmead Hospital.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Nov 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Nov 12
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.